1,123 results on '"LORUSSO V"'
Search Results
202. Cost of skeletal-related events in European patients with solid tumours and bone metastases: data from a prospective multinational observational study
203. Double biochemical modulation of 5-fluorouracil by methotrexate and levo-folinic acid in treatment of advanced digestive tract malignancies
204. Factors that influence achievment of complete remission and its duration after polychemotherapy in follicular non Hodgikin's lymphoma
205. Damaging effects of gliadin on three-dimensional cell culture model
206. O5 Progression free survival (PFS) and overall survival (OS) in patients receiving 3 targeted therapies (TTs) for metastatic renal cell carcinoma (mRCC)
207. Retrospective analysis of Erlotinib in the treatment of patients over 70years with NSCLC: Our experience in the Geriatric Oncologic Unit
208. Prognostic Factors and Validation of Prognostic Nomograms in Patients (PTS) Treated with 3 Targeted Therapies (TTS) for Metastatic Renal Cell Carcinoma (MRCC): Results from an Italian Survey
209. P4-16-09: Health Resource Utilization (HRU) Associated with Skeletal-Related Events (SREs) in Advanced Breast Cancer Patients with Bone Metastases: Results from a Prospective Multinational Observational Study.
210. PCN115 Cost of Skeletal-Related Events (SREs) in Patients with Bone Metastases to solid Tumours Based on the Health Resource Utilisation (HRU) Collected in a Prospective European Multinational Observational Study
211. 3613 POSTER Health Resource Utilization (HRU) Associated With Skeletal-related Events (SREs) by Tumour Type in Patients With Bone Metastases/lesions: European Analysis of a Prospective Multinational Observational Study
212. Sequential use of sorafenib and sunitinib in advanced renal cell carcinoma: does the order of sequencing matter?
213. Health resource utilization (HRU) associated with skeletal-related events (SREs) in patients with bone metastases (BM): Results of a prospective multinational observational study.
214. How often is the planned dose intensity of XELOX and FOLFOX administered to colon cancer patients older than age 65 in clinical practice?
215. Prognostic and predictive value of HER2 extracellular domain in patients with early and metastatic breast cancer treated with trastuzumab and lapatinib: Correlation with clinicopathological parameters and response.
216. A multicenter randomized phase III trial of nonpegylated liposome-encapsulated doxorubicin citrate plus cyclophosphamide (MC) versus liposome-encapsulated doxorubicin citrate plus vinorelbine (MV) as first-line treatment in locally advanced (LABC) or metastatic breast cancer (MBC).
217. Prognostic significance of serum HE4 in epithelial ovarian cancer.
218. Body mass index (BMI) and prognosis in women with metastatic breast cancer (MBC).
219. Inanspruchnahme von Gesundheitsleistungen (HRU) im Zusammenhang mit skelettalen Ereignissen (SRE) bei Patienten mit Knochenmetastasen und Brustkrebs: Ergebnisse einer prospektiven multinationalen europäischen Beobachtungsstudie
220. PCN76 SKELETAL-RELATED EVENTS IN PATIENTS WITH BONE METASTASES LEAD TO CONSIDERABLE HEALTH RESOURCE UTILISATION IN EUROPE: ANALYSIS OF A MULTINATIONAL OBSERVATIONAL STUDY
221. Epirubicin (E) in combination with cisplatin (CDDP) and capecitabine (C) versus docetaxel (D) combined with 5-fluorouracil (5-FU) by continuous infusion as front-line therapy in patients with advanced gastric cancer (AGC): Preliminary results of a randomized phase II trial of the Gruppo Oncologico Dell'Italia Meridionale.
222. Castration-Resistant Prostate Cancer: Targeted Therapies
223. Development of a Multiplex PCR for Rapid Detection of Verocytotoxin-Producing Escherichia coli O26 in Raw Milk and Ground Beef
224. L30 - Possible predictive role of the soluble cd40 ligand (scd40l) in metastatic pancreatic ductal adenocarcinoma (PDAC) patients (pts) treated with first line folfirinox or gemcitabine/nab-paclitaxel combination
225. L10 - Final results of the gideon study according to patient etiology: The italian experience
226. L11 - Hepatocellular Carcinoma In Elderly Patients: final results of The Italian Cohort Of GIDEON (Global Investigational of therapeutic DEcisions in HCC and of its treatment with sorafeNib) Study
227. B03 - Sequential combination of low dose chemo-modulating Temozolomide and Fotemustine in metastatic melanoma: clinical and molecular evaluation
228. Microsatellite Instability (MSI) as Genomic Marker in Endometrial Cancer: Toward Scientific Evidences
229. 51 GASTROINTESTINAL METASTASIS OF NSCLC: A CASE REPORT AND LITERATURE REVIEW
230. TOXOPLASMOSIS: FOOD SAFETY AND RISK COMMUNICATION
231. Cardiac safety of nonpegylated liposomal doxorubicin in patients with advanced breast cancer treated with myocet plus vinorelbine or myocet plus cyclophosphamide in a randomized phase II trial.
232. Atypical appendicitis: diagnostic value of volume-rendered reconstructions obtained with 16-slice multidetector-row CT
233. VARATIONS IN CASEIN PERCENTAGE WITH REFERENCE TO CONTENTS OF SOMATIC CELLS IN MILK OF COWS BRED IN DISTRICT OF BARI
234. First-line cisplatin (P) with docetaxel (TXT) or vinorelbine (VNR) in patients with advanced non-small cell lung cancer: A randomized phase II trial of the Gruppo Oncologico Italia Meridionale
235. New biweekly combination of trastuzumab, docetaxel, and gemcitabine for HER2-positive metastatic breast cancer: First early results from a phase II multicentric trial on behalf of Gruppo Oncologico Italia Meridionale
236. FOLFIRI + bevacizumab as first-line treatment in advanced colorectal cancer (ACC): Final results (prot. GOIM 2601)
237. Bi-weekly administration of capecitabine + oxaliplatin (Xelox-2) in first-line treatment of advanced colorectal cancer (ACRC): A phase II study of the Gruppo Oncologico dell’Italia Meridionale (GOIM)
238. A multicenter randomized phase II study of nonpegylated liposomal doxorubicin plus vinorelbine versus nonpegylated liposomal doxorubicin plus cyclophosphamide as first line in locally advanced breast cancer (LABC) or metastatic breast cancer (MBC): Safety results
239. Escherichia coli O26 IN RAW BUFFALO MILK: PRELIMINARY RESULTS
240. Escherichia coli O26 in minced beef: Prevalence, characterization and antimicrobial resistance pattern
241. Bi-weekly administration of capecitabine+oxaliplatin (XELOX-2) in first line treatment of advanced colorectal cancer (ACRC): Preliminary results
242. First-line cisplatin (P) with docetaxel (TXT) or vinorelbine (VNR) in patients with advanced non-small-cell lung cancer: A phase II randomized trial of Gruppo Oncologico Italia Meridionale
243. Bevacizumab+folfiri as first-line treatment in advanced colorectal cancer (ACC): A multicenter phase II study of the Gruppo Oncologico dell’ Italia Meridionale (prot. GOIM 2601)
244. Folfiri versus xeliri in untreated advanced colorectal cancer: A phase II randomised trial of the Gruppo Oncologico dell’ Italia Meridionale (prot. GOIM 2405)
245. Randomized, multicenter, phase III trial of docetaxel plus epirubicin (ET) with or without capecitabine (X) as first-line therapy for stage IV breast cancer (BC)
246. Oxaliplatin, irinotecan, and 5-fluorouracil/leucovorin in advanced gastric adenocarcinoma: A phase II trial
247. Time to first tumor progression as outcome predictor of a second trastuzumab-based therapy beyond progression in HER2-positive metastatic breast cancer
248. Pegylated liposomal doxorubicin and gemcitabine in the front-line treatment of recurrent/metastatic breast cancer: a multicentre phase II study
249. Vinorelbine plus capecitabine in salvage therapy of breast cancer. Comparison of intravenous vs oral administration of vinorelbine
250. Bevacizumab + folfiri as first-line treatment in advanced colorectal cancer (ACC): A multicenter phase II study of the Gruppo Oncologico dell'Italia Meridionale (prot. GOIM 2601)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.